Bank Of New York Mellon Corp Protagonist Therapeutics, Inc Transaction History

Bank Of New York Mellon Corp

$528 Trillion
Q2 2024

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$7.36 - $11.17 $1.21 Million - $1.84 Million	164,325 New	164,325 $1.79 Million
Q3 2022 Nov 14, 2022	BUY	$7.86 - $11.71 $125,665 - $187,219	15,988 Added 11.25%	158,059 $1.33 Million
Q2 2022 Aug 15, 2022	BUY	$7.06 - $25.52 $16,252 - $58,747	2,302 Added 1.65%	142,071 $1.12 Million
Q1 2022 May 11, 2022	BUY	$23.34 - $36.08 $29,758 - $46,002	1,275 Added 0.92%	139,769 $3.31 Million
Q4 2021 Feb 11, 2022	BUY	$17.63 - $37.1 $129,774 - $273,093	7,361 Added 5.61%	138,494 $4.74 Million
Q3 2021 Nov 12, 2021	SELL	$12.95 - $49.69 $196,801 - $755,138	-15,197 Reduced 10.39%	131,133 $2.32 Million
Q2 2021 Aug 11, 2021	BUY	$25.57 - $44.88 $325,633 - $571,546	12,735 Added 9.53%	146,330 $6.57 Million
Q1 2021 May 13, 2021	BUY	$19.02 - $31.15 $81,614 - $133,664	4,291 Added 3.32%	133,595 $3.46 Million
Q4 2020 Feb 09, 2021	BUY	$18.49 - $25.13 $644,376 - $875,780	34,850 Added 36.9%	129,304 $2.61 Million
Q3 2020 Nov 12, 2020	SELL	$15.19 - $22.4 $104,780 - $154,515	-6,898 Reduced 6.81%	94,454 $1.85 Million
Q2 2020 Aug 12, 2020	BUY	$6.19 - $18.84 $109,990 - $334,767	17,769 Added 21.26%	101,352 $1.79 Million
Q1 2020 May 06, 2020	BUY	$5.4 - $9.22 $5 - $9	1 Added 0.0%	83,583 $590,000
Q4 2019 Feb 14, 2020	BUY	$4.69 - $13.45 $28,984 - $83,121	6,180 Added 7.98%	83,582 $589,000
Q3 2019 Nov 07, 2019	SELL	$9.41 - $16.56 $251,115 - $441,920	-26,686 Reduced 25.64%	77,402 $929,000
Q2 2019 Aug 12, 2019	BUY	$8.98 - $12.96 $368,646 - $532,033	41,052 Added 65.12%	104,088 $1.26 Million
Q1 2019 May 14, 2019	SELL	$6.5 - $13.77 $1,514 - $3,208	-233 Reduced 0.37%	63,036 $792,000
Q2 2018 Aug 06, 2018	BUY	$5.99 - $9.1 $79,684 - $121,057	13,303 Added 26.62%	63,269 $426,000
Q1 2018 May 15, 2018	BUY	$8.46 - $23.08 $46,470 - $126,778	5,493 Added 12.35%	49,966 $430,000
Q4 2017 Feb 09, 2018	BUY	$14.47 - $20.8 $643,524 - $925,038	44,473	44,473 $925,000

Others Institutions Holding PTGX

# of Institutions

212

Shares Held

59.1M

Call Options Held

19K

Put Options Held

107K

Farallon Capital Management LLC San Francisco, CA

5.84M
Shares

$268 Million
0.98% of portfolio
Black Rock Inc. New York, NY

5.76M
Shares

$264 Million
0.0% of portfolio
Rtw Investments, LP New York, NY

5.29M
Shares

$242 Million
3.06% of portfolio
Bvf Inc San Francisco, CA

3.32M
Shares

$152 Million
3.52% of portfolio
Vanguard Group Inc Valley Forge, PA

3.24M
Shares

$149 Million
0.0% of portfolio

View Full List

About Protagonist Therapeutics, Inc

Ticker PTGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,084,100
Market Cap $2.25B
Description
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...

More about PTGX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

News

Stay updated on Bank Of New York Mellon Corp with notifications on news.

Account